Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study
Main finding · SICMResult — go to the resultHazard ratio 0.78 95% CI 0.71–0.86Authors' conclusion
Among patients with T2D and sepsis, SGLT2is were associated with a lower risk of SICM and improved long-term cardiovascular outcomes, compared to DPP4is therapy.
Study context
- Population
- Adults with T2D and infection/sepsismatched cohort
- Participants
- 73,069 vs 73,069
- Exposure
- SGLT2is vs DPP4is
- SGLT2isn = 73,069
- DPP4isn = 73,069reference
- Outcome
- Sepsis-induced cardiomyopathy (SICM)
- Follow-up
- 30 days
Methodological detailspropensity score matched (1:1), TriNetX global health research network
- Propensity score matched (1:1)
- TriNetX global health research network
Main finding
SICM
Hazard ratio
0.78
95% CI 0.71–0.86
P < 0.001
SGLT2is vs DPP4is
HR 0.78 (95% CI 0.71–0.86); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality · 1 year | 0.58 (0.55–0.62) | P < 0.001 | |
| Hospitalisation · 1 year | 0.83 (0.79–0.87) | P < 0.001 | |
| MACE · 1 year | 0.86 (0.80–0.93) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Subgroup analyses and negative control outcomes
- Supported the robustness of the findings
Original publication
Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study. Crit Care. Published 27 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →